Resultados de Búsqueda

NICE

National Institute for Health and Clinical Excellence (NICE)

Base decisions on the timing of regular clinical reviews and follow‑up imaging for people with brain metastases on:: extracranial disease status, life expectancy, primary cancer, the person's preferences, treatment options available. Consider standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as part of regular clinical review for people with brain metastases, to assess for progression or recurrence, unless MRI is ...

NICE

National Institute for Health and Clinical Excellence (NICE)

To help establish current disease status, offer extracranial imaging (appropriate to the primary tumour type) to people with any radiologically suspected brain metastases that may be suitable for focal treatment. Perform all intracranial and extracranial diagnostic imaging and, if appropriate, biopsy of extracranial disease, before referral to the neuro-oncology multidisciplinary team. In the absence of evidence, the committee recommended standard structural MRI based on their experience, ...

NICE

National Institute for Health and Clinical Excellence (NICE)

These recommendations are not intended to affect treatment with eltrombopag that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

NICE

National Institute for Health and Clinical Excellence (NICE)

These recommendations are not intended to affect treatment with romiplostim that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

NICE

National Institute for Health and Clinical Excellence (NICE)

The case for adopting Memokath‑051 for treating ureteric obstruction is partially supported by the evidence. The evidence is limited but suggests that in selected cases, Memokath‑051 is effective at relieving ureteric obstruction and improving quality of life. When inserted by trained clinicians and in appropriate patients, Memokath‑051 is associated with equivalent success rates and a better patient experience compared with double‑J stents. Using Memokath‑051 may also reduce the ...